Dose-range Finding Study of BF2.649 Effect on Patients With Obstructive Sleep Apnea (OSA)
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Excessive Daytime Sleepiness
Related studies linked through entity extraction aliases.
BF2.649 in Patients With OSA, Still Complaining of EDS and Refusing to be Treated by CPAP.
- Status
- COMPLETED
- Phase
- PHASE3
BF2.649 in Patients With OSA and Treated by CPAP But Still Complaining of EDS
- Status
- COMPLETED
- Phase
- PHASE3
Efficacy and Safety Study of BF2.649 and BF2.649 Add on Modafinil on Cataplexy in Patients With Narcolespy
- Status
- COMPLETED
- Phase
- PHASE3
Efficacy and Safety Study of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy
- Status
- COMPLETED
- Phase
- PHASE3
A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With Narcolepsy
- Status
- COMPLETED
- Phase
- PHASE2
Dose Range Finding Study of BF2.649 Versus Placebo to Treat Excessive Daytime Sleepiness in Parkinson's Disease Patients
- Status
- COMPLETED
- Phase
- PHASE2
Treatment of Refractory Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea/Hypopnea Syndrome (OSA/HS) Using Nasal Continuous Positive Airway Pressure (nCPAP) Therapy (0249-015)
- Status
- TERMINATED
- Phase
- PHASE2
Sedating Antidepressant Improves Driving Safety in Patients With Major Depressive Disorder
- Status
- COMPLETED
- Phase
- PHASE2
Study to Assess Patient Reported Outcomes With Armodafinil Treatment for Excessive Sleepiness in Adults With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome
- Status
- COMPLETED
- Phase
- PHASE3
Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive Sleepiness
- Status
- COMPLETED
- Phase
- PHASE3